Harmony Biosciences (HRMY) Tops Q2 EPS by 9c

Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $0.57, $0.09 better than the analyst estimate of $0.48. Revenue for the quarter came in at $107 million versus the consensus estimate of $100.73 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Tutor Perini launches $400M senior notes offering due 2033
• Dutch Bros Inc. (BROS) PT Raised to $90 at DA Davidson on Sales/Earnings Upside